iCo Therapeutics (iCo Therapeutics) Change In Payables And Accrued Expense : $0.62 Mil (TTM As of Mar. 2021)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Change In Payables And Accrued Expense?

iCo Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2021 was $0.50 Mil. It means iCo Therapeutics's Accounts Payable & Accrued Expense increased by $0.50 Mil from Dec. 2020 to Mar. 2021 .

iCo Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2020 was $0.38 Mil. It means iCo Therapeutics's Accounts Payable & Accrued Expense increased by $0.38 Mil from Dec. 2019 to Dec. 2020 .

iCo Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for iCo Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Change In Payables And Accrued Expense Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.02

0.12

0.38

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.24	-0.02	-0.02	0.16	0.50

iCo Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.62 Mil.

iCo Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines